It is made available under a CC-BY-NC-ND 4.0 International license .

1	A Personalized Probabilistic Approach to Ovarian Cancer Diagnostics
2	Dongjo Ban ¹ , Stephen N. Housley ¹ , Lilya V. Matyunina ¹ , L. DeEtte McDonald ¹ , Victoria L.
3	Bae-Jump ² , Benedict B. Benigno ³ , Jeffrey Skolnick ^{1,4} , and John F. McDonald ¹ *
4	
5	¹ Integrated Cancer Research Center, School of Biological Sciences, Georgia Institute of
6	Technology, 315 Ferst Drive, Atlanta, GA 30332 USA
7	² Department of Obstetrics and Gynecology, University of North Carolina, 3009 Old Clinic
8	Building, Chapel Hill, NC 27599, USA
9	³ Ovarian Cancer Institute, 1266 W. Paces Ferry Rd NW #339, Atlanta, GA 30327, USA
10	⁴ Center for the Study of Systems Biology, School of Biological Sciences, Georgia Institute of
11	Technology, 315 Ferst Drive, Atlanta, GA 30332, USA
12	
13	
14	*Corresponding author: 315 Ferst Drive, Atlanta, GA 30332, USA; 404-550-7214;
15	john.mcdonald@biology.gatech.edu
16	
17	
18 19 20 21 22 23 24 25 26 27 28 29	 HIGHLIGHTS Predictive models derived from machine learning (ML) analyses of serum metabolic profiles can accurately (PPV 93%) detect ovarian cancer (OC). Only a minority of the most predictively informative metabolites are currently annotated (7%). Lipids predominate among the most predictively informative metabolites currently annotated. The frequency distribution of model-derived patient scores can be used to develop a useful clinical tool for the diagnosis of OC.

It is made available under a CC-BY-NC-ND 4.0 International license .

30 Abstract

31

Objective. The identification/development of a machine learning (ML)-based classifier 32 33 that utilizes metabolic profiles of serum samples to accurately identify individuals with ovarian 34 cancer (OC). 35 Methods. Serum samples collected from 431 OC patients and 133 normal women at four 36 geographic locations were analyzed by mass spectrometry. Reliable metabolites were identified 37 using recursive feature elimination (RFE) coupled with repeated cross-validation (CV) and used 38 to develop a consensus classifier able to distinguish cancer from non-cancer. The probabilities 39 assigned to individuals by the model were used to create a clinical tool that assigns a likelihood 40 that an individual patient sample is cancer or normal. 41 *Results.* Our consensus classification model is able to distinguish cancer from control 42 samples with 93% accuracy. The frequency distribution of individual patient scores was used to 43 develop a clinical tool that assigns a likelihood that an individual patient does or does not have 44 cancer. 45 *Conclusions*. An integrative approach using metabolomic profiles and ML-based 46 classifiers has been employed to develop a clinical tool that assigns a probability that an 47 individual patient does or does not have OC. This personalized/probabilistic approach to cancer 48 diagnostics is more clinically informative and accurate than traditional binary (yes/no) tests and 49 represents a promising new direction in the early detection of OC. 50

51 **1. Introduction**

It is made available under a CC-BY-NC-ND 4.0 International license .

52 Early cancer diagnosis is one of the most important contributing factors to the successful 53 treatment of the disease [1]. Early diagnosis is especially challenging for cancers like ovarian 54 cancer (OC) that can progress rapidly, and yet display little to no clinical symptoms early in their 55 development [2]. The ideal cancer diagnostic should not only be highly accurate, but additionally 56 non-invasive and low cost to be widely available to the general public. Despite heroic efforts to 57 develop such cancer diagnostics over the last several decades, this goal has proven to be 58 frustratingly elusive [3]. A major reason for this is that, on the molecular level, cancer is a highly 59 heterogenous disease not only between different types of cancer but even among individuals with 60 the same cancer type [4]. As a consequence, finding a single molecular biomarker or set of 61 biomarkers that are universally shared among individuals with even the same type of cancer is 62 extremely difficult.

63 In recent years, various computational methods, including machine learning (ML), have 64 been applied in efforts to identify patterns embedded within large omics datasets (e.g., 65 genomic/proteomic/metabolomic) that may constitute an accurate diagnostic of cancer [5], [6] 66 and other diseases [7]. For example, perturbations of metabolic levels in the blood and/or other 67 body fluids have long been considered promising indicators of cancer and other diseases [8], [9] 68 because metabolites constitute end points of many, if not most, of the molecular processes 69 underlying biological functions. As such, metabolic profiles have been proposed as a molecular 70 phenotype of biological systems, reflective of collective information encoded at the genome 71 level and realized at the transcriptome and proteome levels [10].

Despite the inherent advantages of metabolic patterns as biomarkers of cancer and other diseases, extreme care is required in both the selection and analysis of metabolomic datasets. For example, potential technical inconsistencies in data acquisition (*e.g.*, variation in sensitivity

It is made available under a CC-BY-NC-ND 4.0 International license .

75	between instruments/laboratories and/or analytic drift associated with the same instrument over
76	time) can easily compromise the reliability of acquired datasets unless frequent standardization
77	with control samples is employed throughout the analytic process. In addition, extra precaution
78	is needed in both the computational analysis of metabolic and other omics datasets and the
79	interpretation of results. For example, there are a variety of ML approaches to the analysis of
80	omics data, and each is associated with individual strengths and weaknesses [11], [12]. Despite
81	these challenges, the use of metabolomic and other omics profiles as early indicators of cancer is
82	not insurmountable and may provide clinicians with a powerful and highly accurate tool for
83	personalized cancer diagnosis when properly addressed.
84	We report here on the development of a ML-based approach for the early detection of OC
85	using metabolomic profiles in blood. Analyses were carried out on serum samples collected from
86	431 OC patients and 133 normal women at four geographic locations in the United States and
87	Canada. The utility of a consensus classifier was evaluated using four independent sets of
88	metabolomic profiles. Combining the best predictions from each profile using the consensus
89	classifier resulted in a final set of predictions that can distinguish cancer from control samples
90	with high accuracy (PPV 93%). We illustrate how the frequency distribution of individual patient
91	scores can be used to develop a useful clinical tool that may be used to assign a likelihood that an
92	individual does or does not have OC.
93	

94 **2. Methods**

Details of the extensive methods employed in this study are presented in the
Supplementary Material. Briefly, 431 serous papillary OC and 133 normal serum samples were
obtained from four geographic locations (Atlanta, GA, Philadelphia, PA, Chapel Hill, NC, and

It is made available under a CC-BY-NC-ND 4.0 International license .

98	Alberta, Canada) and were transferred to Creative Proteomics laboratory (Shirley, NY) for ultra-
99	performance liquid chromatography, high-resolution mass spectrometry (UPLC-MS) analysis. A
100	pooled quality control sample was obtained by combing equal amounts of each of the individual
101	OC and control serum samples. Samples were individually processed through two different
102	columns and analyzed using two different ionization modes (negative and positive) resulting in
103	four distinct datasets (HP: HILIC positive; HN: HILIC negative; RN: C ₁₈ reversed phase
104	negative; RP: C ₁₈ reversed phase positive). Reliable features (metabolites) were identified using
105	recursive feature elimination (RFE) coupled with repeated cross-validation (CV). The output
106	from these processing steps for each of the four datasets was an assignment of a relative ranking
107	of features reflective of the relative frequencies of the features after repeated CV iterations. A
108	consensus classifier was constructed by aggregating the results of five independent ML
109	classifiers [logistic regression (LRC), random forest (RFC), support vector machine (SVM), k-
110	nearest neighbor (KNN), and adaptive boosting (ADA)] to generate predictive classification
111	models. The probabilities assigned to individuals by the consensus model were utilized to create
112	a background distribution of probabilities that a given sample was cancer or normal.
113	
114	3. Results
115	
116	3.1 Data acquisition
117	
118	The data acquisition process for this study is summarized in Figure 1A. Serum samples
119	collected from 431 OC patients and 133 non-cancerous/normal individuals were obtained from
120	four geographic locations in the United States (Fox Chase Cancer Center-Philadelphia, PA;

It is made available under a CC-BY-NC-ND 4.0 International license .

121 UNC-Chapel Hill, NC; Northside Hospital-Atlanta, GA, and Canada-Alberta Health Services-

- 122 Alberta, BC). Samples were characterized using ultra-performance liquid chromatography
- 123 coupled with tandem mass spectrometry (UPLC-MS/MS). Each serum sample was
- 124 independently processed through two different columns (HILIC and C₁₈ reversed phase) and
- 125 analyzed using two different ionization modes (negative and positive) resulting in four distinct
- 126 datasets during MS/MS (HP: HILIC positive; HN: HILIC negative; RN: C₁₈ reversed phase
- 127 negative; RP: C₁₈ reversed phase positive). Because of the large number of samples,
- 128 metabolomic analyses were conducted over two separate batches. To detect and correct
- 129 instrument drift within and between runs, a pooled quality control (QC) sample was run

130 following analysis of every ten patient samples. A scatter plot of principle component analyses

131 performed on the preprocessed data confirmed that no significant experimental variation was

132 detected between batches after quality control of the data (Fig. 1B).



133

Fig. 1. Workflow diagram illustrating data acquisition and preparation process. A) Serum samples from ovarian
 cancer patients and non-cancerous individuals are collected from multiple geolocations. They are analyzed using
 UPLC-MS/MS in an untargeted workflow to characterize the metabolome of ovarian cancer patients. Normalization
 and filtering of the features are performed following the best practices to obtain the preprocessed metabolomic

138 profiles for downstream analyses. B) Scatter plot of principal component analysis performed on the preprocessed

It is made available under a CC-BY-NC-ND 4.0 International license .

data after accounting for systematic and random errors. QC samples (orange) are shown to mostly cluster togetherwith no clear separation between the two batches, indicating unwanted experimental variation has been eliminated.

141

142 3.2 Assessing the Stability of Metabolomic Features

143

144 The overall goal of our study is the identification/development of a ML classifier that 145 utilizes metabolic profiles to accurately distinguish individuals with or without OC. Toward this

end, we independently examined the predictive accuracy of five ML classifiers for each of the

147 four datasets: RFC, SVC, ADA, KNN, and LRC.

148 Prior to the independent evaluation of each of these classifiers, we identified reliable

149 features (metabolites) with recursive feature elimination (RFE) [13] coupled with repeated cross-

150 validation (CV). The output from these processing steps for each of the four datasets was an

assignment of a relative ranking of features reflective of the relative frequencies of the features

after repeated CV iterations, as well as their relative contribution levels as determined by the

153 Gini importance scores (see Methods in Supplementary Material for details).

Across all four datasets, we observed a moderate positive correlation (HN: R = 0.26, p < 0.001; HP: R = 0.56, p < 0.001; RN: R = 0.39, p < 0.001; RP: R = 0.50, p < 0.001) between the relative frequency of features and their importance (Fig. 2). This trend is most apparent in the RP dataset where the vast majority of features of high importance were in high frequency. In contrast, the HP dataset displayed a number of lower frequency features of high Gini importance (See Methods in Supplementary Material for details).

It is made available under a CC-BY-NC-ND 4.0 International license .



161 Fig. 2. The frequency and Gini importance values of features in each dataset. The x-axis and y-axis correspond 162 to feature frequency and importance value, respectively. The weights computed by combining frequencies 163 and importance values were represented by the sizes and opacity of the points. The analysis revealed that 164 across all datasets, many features had high frequency but relatively lower levels of importance. The HN 165 dataset exhibited the smallest range of importance values, while most features were observed frequently. 166 The RN and HP datasets showed a similar pattern, with the HP dataset being particularly noteworthy due 167 to a subset of features displaying lower frequencies but higher importance values. The RP dataset 168 displayed the largest number of features with high levels of both frequency and importance values.

169



179 3.3 Evaluation of Classifier Performance

It is made available under a CC-BY-NC-ND 4.0 International license .

181	Prior to the evaluation of the classifier performance, a neural network based autoencoder
182	was used to reduce the dimensionality of the datasets while preserving informative representation
183	of the original (Supplementary Fig. 6). Using the compressed dataset, the ability of each of the
184	five classifiers (RFC, SVC, ADA, KNN, LRC) to correctly identify cancer samples and non-
185	cancer controls was independently evaluated using four metrics: 1) Positive predictive value
186	(PPV, a.k.a. precision), 2) negative predictive value (NPV), 3) f1-score (F1), and 4) Matthew's
187	correlation coefficient (MCC). PPV (precision) is the number of true positives divided by the
188	number of true positives plus false positives (potential range: 0-100%), while NPV is the number
189	of true negatives divided by the number of true negatives plus false negatives (potential range: 0-
190	100%). The f1-score, which symmetrically represents both precision and recall in a single metric,
191	is the harmonic mean of precision and recall (a.k.a. sensitivity; potential range: 0-100%). MCC
192	reflects the correlation between the observed and predicted binary classifications (potential
193	range: -1 to +1). An MCC of +1 represents a perfect prediction, 0 no better than a random
194	prediction and -1 indicates total disagreement between predictions and observations. MCC
195	considers true and false positives and negatives and is generally regarded as a balanced measure
196	of predictive accuracy even if the classes are of very different sizes [14]. The performance of
197	each of the five classifiers and the consensus classifier based on repeated cross-validation is
198	presented in Table 1.

199 200 Table 1

201 Performance evaluation metrics for individual and consensus classifier

Dataset	Classifier	PPV	NPV	F1	MCC	Dataset	Classifier	PPV	NPV	F1	MCC
HN	SVC	97%	88%	95%	0.86	RN	Consensus	97%	90%	95%	0.86
	Consensus	96%	89%	95%	0.85		SVC	97%	88%	95%	0.86
	KNN	96%	88%	94%	0.83		LRC	97%	88%	95%	0.85
	LRC	95%	89%	94%	0.83		ADA	96%	91%	95%	0.85

It is made available under a CC-BY-NC-ND 4.0 International license .

	ADA	95%	90%	94%	0.83		KNN	95%	90%	94%	0.84
	RFC	95%	88%	93%	0.82		RFC	95%	92%	94%	0.84
	Consensus	95%	89%	94%	0.82	RP	Consensus	96%	92%	95%	0.87
	SVC	95%	88%	93%	0.82		SVC	96%	91%	95%	0.85
IID	KNN	94%	88%	93%	0.79		KNN	95%	90%	94%	0.84
ΠP	LRC	94%	87%	92%	0.78		LRC	95%	90%	94%	0.83
	ADA	93%	91%	93%	0.8		ADA	95%	93%	94%	0.84
	RFC	93%	88%	92%	0.78		RFC	94%	92%	93%	0.81

203 204	While the performance of the individual and consensus classifiers varied across different
205	datasets, the differences were minor. The HP dataset displayed a slightly lower performance
206	relative to the HN, RN, and RP datasets. However, the overall performance was consistently high
207	across the four datasets (PPV \ge 93%; NPV \ge 87%; F1 \ge 92%; MCC \ge 0.78; Fig. 3A). The
208	cumulative confusion matrix from the consensus classifier (Fig. 3B) is generally consistent with
209	these results demonstrating a relatively low misclassification rate of false negatives (~2 to 3%)
210	and slightly higher rate of false positives (~11 to17%).





Fig. 3. Comparison of consensus classifier performance. A) The performance characteristics of the models were graphically represented through precision-recall (PR) curves. Besides the HP dataset, the models for the remaining

It is made available under a CC-BY-NC-ND 4.0 International license .

214 datasets showed similar levels of performance. B) Cumulative confusion matrices, also compiled from repeated CV,

- 215 further reinforced these observations despite the false positives (FP) and false negatives (FN).
- 216

217 *3.4 Utility of class probabilities as background distributions*

218

The results of the repeated cross-validation scores can be used to assign a mean probability (adjusted to fall within a -2 to 2 range) that signifies the certainty of either a cancerous or non-cancerous classification. These probabilities were averaged for each sample and the distributions for each of the four datasets are displayed in Fig. 4A. The results highlight the classifier's ability to clearly distinguish between cancerous and non-cancerous samples in all four datasets.

225 By combining results from the four datasets and selecting the best average score among 226 them, we observed a notable improvement in classifying both cancer and normal samples. This 227 underscores that each dataset brings its unique contribution to the accurate prediction of cancer 228 or non-cancer status (Fig 4B). A striking 97% of the cancer samples scored within the 1.0-2.0 229 range, with no (0%) misclassification of non-cancerous samples (Supplementary Table 7). In 230 contrast, 83% of the non-cancerous/normal samples were found to fall within the -2.0 to -1.0 231 score range indicating that our consensus classifier is better at predicting cancer than non-cancer. 232 When binary classification results for the cancer samples are subdivided into early-stage 233 (Stage I/II) and late-stage (Stage III/IV) cancer groups, the classifier still demonstrates high 234 accuracy. It not only identifies late-stage cancer samples effectively but also classifies early-235 stage samples accurately. This holds true when considering both individual scores (Figure 4C) 236 and best scores (Figure 4D). Using the best scores, the classifier's predictive accuracy reaches 237 98% for early-stage samples and 92.7% for late-stage cancers for score range 1.5-2

It is made available under a CC-BY-NC-ND 4.0 International license .

238 (Supplementary Table 7). Adoption of our proposed workflow in a clinical setting would enable





241

242 Fig. 4. Evidence for the classifier's ability to clearly distinguish between cancerous and non-cancerous samples. A) 243 The bar charts exhibit the distributions of scores that have been converted from class probabilities and ranged from -244 2 to 2 to improve visual clarity. The scores represent averages obtained from repeated cross-validation (CV) for each 245 sample. Clear differentiation can be observed between the scores of cancer (red) and normal (blue) samples across 246 all four datasets. The peaks in the distributions indicate the most frequently occurring score range for the samples. 247 B) Similar to the previous bar chart, this figure illustrates the best average score across the four datasets

It is made available under a CC-BY-NC-ND 4.0 International license .

248 demonstrating a notable improvement in classifying both cancer and normal classes. C) The bar chart illustrates the 249 distribution of samples across various score ranges. This revealed that early- and late-stage samples clearly 250 distinguish themselves from the normal samples. D) In an analogous manner to figure B), selecting the best score 251 improves the final score for the scores at the stage-level. E) Diagram visualizing the potential adoption of the 252 proposed workflow in a clinical setting. Given the absence of approved screening methods for ovarian cancer, this 253 approach enables women to undergo serum profiling at a clinic to predict their cancer status. This could result in 254 three possible scenarios: an individual's serum profile (X) falls within a score range where misdiagnosis is unlikely, 255 enabling a confident ruling out of a cancer diagnosis. An individual's score (Y) falls within a range where 94% of 256 others with this score have been diagnosed with cancer. Lastly, determining the cancer status of an individual (Z) 257 may be challenging, as there are only a few samples within this score range and it is in the middle of the distribution.

258 4. Discussion

259	Although the incidence of OC is relatively low (2.5% of all malignancies in women [15]),
260	it is among the most lethal of all cancers due to its high mortality rate. The reason for this is
261	largely attributable to the fact that the disease is not typically diagnosed until the late (post-
262	metastatic) stages of development (Stage III/IV) when effective treatment is difficult. For
263	example, the most common sub-type of OC, serous papillary (65% of OC patients), is typically
264	not diagnosed until Stage III/IV when the 5-year survival rate is only 31%. In contrast, if the
265	disease is identified and treated early in its development (Stage I/II), the 5-year survival rate is
266	93%. These statistics dramatically underscore the dire need for an early diagnostic test for OC
267	and other cancers where early-stage clinical symptoms are virtually non-existent.
268	The traditional approach for the identification of non-invasive biomarkers of cancer has
269	been the screening of blood (or other body fluids) in search of significant changes in the
270	presence/levels of molecules (typically proteins) associated with the disease [16]. A well-known
271	example of such a diagnostic is the PSA (prostate specific antigen) biomarker for prostate cancer
272	[17].
273	The OC biomarker candidate, CA125 (a.k.a., mucin 16/ MUC16) [18] was first
274	introduced in 1996 [19]. Although an elevated level of CA125 is detected in ~90% of late stage
275	(III/IV) OC patients, it is elevated in only ~50% of early-stage patients making it a poor
276	biomarker of early-stage disease with a PPV of only ~30% [20]. In 2003, a second candidate

It is made available under a CC-BY-NC-ND 4.0 International license .

biomarker for OC, HE4 (human epididymis protein), was introduced [21]. While HE4 was an
improvement over CA125 in having a reported PPV of ~58%, it is still not sufficiently accurate
to serve as a diagnostic test. Combining the results of the HE4 and CA125 together did not
significantly improve PPV. However, the combination did lead to the development of a logistic
regression model called ROMA (risk of malignancy algorithm) that was approved by FDA in
2011 as a method to classify patients with a pelvic mass into those with high vs. low risk of
having OC [20].

284 By the early 2000s, it was becoming progressively clear that, on the molecular level at 285 least, cancer was a much more complex disease than originally envisioned [4]. This realization 286 was supported by findings indicating the existence of a multitude of disrupted molecular 287 pathways (and underlying mutations) capable of leading to even the same cancer type. Such 288 molecular level heterogeneity among individual cancer patients made the likelihood of 289 identifying one or two biomarkers capable of accurately diagnosing all individuals with even the 290 same type of cancer highly unlikely. As a consequence, the search for more accurate ways to 291 diagnose cancer became focused on exploring larger combinations of biomarkers that might 292 better capture the molecular heterogeneity underlying the disease [22]–[25].

In the case of OC, there were a number of multi-biomarker diagnostic tests developed in the early 2000s [26]–[28]. However, none of these early efforts were sufficiently validated to acquire FDA approval. In 2009, an assay (trade name OVA1) was proposed that incorporated levels of five serum proteins combined with proprietary software to generate high or low probability that an ovarian mass was a malignant tumor [29]. While the test was approved by FDA as a clinical aid in determining if a patient should be referred for further analysis, the test's low PPV (31%) [30] eliminated it from consideration as an effective OC diagnostic. A more

It is made available under a CC-BY-NC-ND 4.0 International license .

300 recent version of the OVA1 test (initially known as OVA2 but now trademarked as OVERA)

301 uses a slightly different set of proteins upon which to generate its predictions. Although an

302 improvement over OVA1, OVERA continues to be associated with a relatively low PPV (~40%)

303 [31], thereby again excluding it as a reliable OC diagnostic.

With the expanded availability of omics technologies and associated datasets (*e.g.*, genomic, transcriptomic, proteomic, metabolomic) in recent years, a new approach to diagnostics began to emerge [32]. The application of various AI (artificial intelligence) approaches, most notably machine learning, to the analysis of large omics datasets of diseased and non-diseased individuals opened the possibility of the identification of patterns by which these categories could be distinguished. Predictive models built upon such classifications might then constitute a new generation of diagnostic tests.

311 While this basic concept is straightforward, its application is certainly not. There are 312 multiple approaches to ML, and each is associated with individual strengths and weaknesses 313 [11], [12]. In addition, the output from ML analyses of omics datasets is heavily dependent upon 314 both the quality and type of data being analyzed. For example, classifiers that are based 315 exclusively on ML analysis of DNA sequence datasets may be appropriate if the onset and 316 progression of the disease in question is exclusively attributable to genetic mutations. Certainly, 317 there is a significant genetic component to cancer, but other environmental (e.g., diet, lifestyle, 318 microbiome, etc.) and molecular (e.g., epigenetic/gene expression changes, gene-gene/protein-319 protein interactions, etc.) factors are also known to play significant roles. Indeed, it has been 320 proposed that the accurate characterization of a complex disease like cancer will ultimately 321 require simultaneous analyses of multi-omics datasets [33]. While this may well be the case, the

It is made available under a CC-BY-NC-ND 4.0 International license .

development of computational methodologies sufficiently complex to accurately characterize
multi-omics datasets is only in its infancy [34], [35].

In lieu of an approach that simultaneously analyzes multi-omics datasets, we chose a currently available alternative, *i.e.*, working with a dataset that reflects biological changes occurring on multiple levels. Metabolic profiles are widely viewed as a molecular phenotype reflective of underlying collective information encoded at the genome level and realized at the transcriptome and proteome levels. As such, metabolic profiles have long been considered promising indicators of cancer and other complex diseases [8], [9].

330 To help ensure the quality of our metabolic data, individual normal and OC patient 331 samples were collected from four geographically divergent locations and analyzed using ultra-332 performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS-333 positive and negative modes and each sample independently pre-processed through two 334 columns) generating four distinct datasets (HN: HILIC negative; HP: HILIC positive; RN: C₁₈ 335 reversed phase negative; RP: C_{18} reversed phase positive). To guard against instrumental drift 336 between runs, the same control samples were analyzed following every ten biological samples. 337 Principle component analyses of data generated from our MS analyses across different batches and times demonstrated little experimental variation between runs. 338

Each of our four datasets was analyzed separately to determine if any particular dataset contained more relevant information than any other. We found little difference in the accuracy of predictions computed using each dataset individually. When we combined the best average score from each of the four datasets, we observed an improvement in the classification of both cancer and normal samples. This suggests that each of the four datasets contribute uniquely to the accurate prediction of cancer status.

It is made available under a CC-BY-NC-ND 4.0 International license .

345 Computationally, we evaluated the performance of five independent ML classifiers. A 346 consensus classifier that generates average predictive probabilities from the probabilities of each 347 of the individual classifiers gave the best overall performance with a PPV of 93%. Interestingly, 348 the overall predictive accuracy of our consensus classifier was better for early-relative to late-349 stage patients. We found that late-stage patients display greater heterogeneity in molecular 350 profiles than early-stage patients. While the reason for this dichotomy is currently unknown, the 351 preliminary findings suggest that OCs may become more metabolically heterogeneous as they 352 progress/metastasize. However, because the sample size of early-stage patients is considerably 353 less than late-stage patients in this study, further analysis of expanded datasets will be required to 354 resolve this issue.

Our model's accuracy in predicting women with OC is slightly greater than its accuracy in predicting women without the disease. The reason for this is currently unknown but may, at least in part, be due to the fact that the model may be detecting disease in women prior to clinical symptoms and clinical diagnosis. Time course studies are currently being instituted to test this hypothesis.

The high PPV (93%) associated with our consensus classifier supports the notion that ML analysis of omics data, and of metabolomic data in particular, is an extremely promising approach for the future diagnosis of ovarian and possibly other cancers as well. Such analyses will likely lead to a more probabilistic approach to cancer diagnosis that will serve to personalize the process much as genomic profiling of individual patient tumors is personalizing cancer treatment (*i.e.*, precision cancer medicine).

366 Despite these highly favorable prospects, it is important to keep in mind the limitations of
367 ML analyses of omics data. For example, the PPV associated with even the same ML based

It is made available under a CC-BY-NC-ND 4.0 International license .

368 predictive model can be highly sensitive to the size and composition of the datasets employed in 369 building and testing the models. For example, in an earlier pilot study of the metabolic profiles of 370 a relatively small number (46) of OC patient samples collected from one of the same areas 371 sampled in our current study (Northside Hospital, Atlanta), the authors generated a predictive 372 model with a putative accuracy of 100% [36]. The relative reduction in accuracy associated with 373 our current model relative to this earlier study coupled with the fact that none of the top ranked 374 features in the earlier study ranked within the top 100 features in our current study 375 (Supplementary Table 8) underscores the impact of datasets on ML/metabolomic based 376 predictive models. Future refinements in the development of metabolomic (and likely all omics) 377 based ML models will need to address the issue of how many samples over what geographic area 378 are needed to reflect the full spectrum of diversity in OC (and other cancer types). 379 In an effort to exemplify how the type of results generated in our study might, in the 380 future, translate into a clinically useful tool, we grouped the quantity and percentage of our

381 samples into score ranges. We envision a clinical tool in which the scores of individual patients 382 can be mapped across such a distribution providing a likelihood that an individual patient does or 383 does not have cancer. Such information could serve as a significant aid in determining the need 384 for treatment or continued monitoring. For example, consider the scenarios presented in Fig. 4F. 385 Scenario (A) represents a situation in which an individual's serum profile falls within a score 386 range that makes cancer highly unlikely. In such a case, the individual may only require yearly 387 monitoring. In scenario (B), the detection is more problematic due to a relatively small number 388 of samples in this score range and a comparable number of cancerous and non-cancerous 389 patients. In such cases, a patient may be referred for more additional and/or more frequent 390 screening. Scenario (C) depicts a situation where an individual's score lies in a range where a

It is made available under a CC-BY-NC-ND 4.0 International license .

- 391 majority (94%) of patients has been diagnosed with cancer. In such a case, the patient would392 likely be referred for immediate advanced screening/treatment.
- 393 In summary, our results confirm the overall potential of an integrative approach using
- 394 metabolomic profiles and ML-based classifiers for the detection of OC. The accuracy of these
- 395 classifiers is highly dependent upon both the quality and quantity of the data upon which models
- 396 are built. We found little difference in the accuracy of predictions generated using alternative
- 397 ML classifiers, although the consensus classifier generated the most accurate predictions.
- 398 Application of results generated from our consensus classifier illustrated how the frequency
- 399 distribution of individual patient scores can be used to develop a useful clinical tool that assigns
- 400 a likelihood that an individual does or does not have OC. We believe this
- 401 personalized/probabilistic approach to cancer diagnostics is more robust and clinically
- 402 informative than the more traditional binary (yes/no) tests and may represent a promising new
- 403 direction in the early detection of OC and perhaps other cancer types as well.
- 404

405 Fundings

- 406 This research was funded by the Ovarian Cancer Institute (Atlanta), the Laura Crandall Brown
- 407 Foundation, the Deborah Nash Endowment Fund, Northside Hospital (Atlanta), and the Mark
- 408 Light Integrated Cancer Research Student Fellowship.
- 409

410 **CRedit authorship contribution statement**

- 411 Dongjo Ban: Conceptualization, Formal analysis, Investigation,
- 412 Methodology, Software, Roles/Writing -original draft. Stephen N. Housley: Formal

It is made available under a CC-BY-NC-ND 4.0 International license .

- 413 analysis, Software, Writing review & editing. Lilya V. Matyunina: Data curation. L. DeEtte
- 414 McDonald: Data curation, Writing review & editing. Victoria L. Bae-Jump: Data curation.
- 415 Benedict B. Benigno: Data curation, Funding acquisition. Jeffrey Skolnick: Formal
- 416 analysis, Writing review & editing. John F.
- 417 McDonald: Conceptualization, Investigation, Project administration,
- 418 Resources, Supervision, Roles/Writing original draft, Writing review & editing.
- 419
- 420 Declaration of Competing Interest
- 421 The authors have no conflict of interest to declare.
- 422

423 Acknowledgements

- 424 We thank Ramit Bharanikumar and Zainab Arshad for their contributions to pilot studies
- 425 related to this project.
- 426

427 Supplementary Material

428 Supplementary material to this article can be found online at https://

429 References

- [1] D. Crosby, S. Bhatia, K.M. Brindle, L.M. Coussens, C. Dive, M. Emberton, et al., Early
 detection of cancer, Science. 375 (2022) eaay9040. doi: 10.1126/science.aay9040.
- 432 [2] C. Stewart, C. Ralyea, S. Lockwood, Ovarian cancer: An integrated review, Semin. Oncol.
- 433 Nurs. 35 (2019) 151-156. doi: 10.1016/j.soncn.2019.02.001.
- 434 [3] J.D. Brooks, Translational genomics: The challenge of developing cancer biomarkers,
 435 Genome Res. 22 (2012) 183–187. doi: 10.1101/gr.124347.111.
- [4] R.A. Burrell, N. McGranahan, J. Bartek, C. Swanton, The causes and consequences of
 genetic heterogeneity in cancer evolution, Nature. 501 (2013) 338-345. doi:
 10.1038/nature12625.
- 439 [5] J.T. Shreve, S.A. Khanani, T. C. Haddad, Artificial intelligence in oncology: Current
 440 capabilities, future opportunities, and ethical considerations, Amer. Soc. Clin. Oncol. Edu.
 441 Book, 42 (2022) 842–851. doi: 10.1200/EDBK 350652.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 442 [6] J.F. McDonald, Back to the future The integration of big data with machine learning is re443 establishing the importance of predictive correlations in ovarian cancer diagnostics and
 444 therapeutics, Gyn. Oncol. 149 (2018) 230–231. doi: 10.1016/j.ygyno.2018.03.053.
- [7] Y. Kumar, A. Koul, R. Singla, M. F. Ijaz, Artificial intelligence in disease diagnosis: a
 systematic literature review, synthesizing framework and future research agenda, J. Ambient
 Intell. Humaniz Comput. 14 (2023) 8459-8486. doi: 10.1007/s12652-021-03612-z.
- [8] C. Beuchel, J. Dittrich, J. Pott, S. Henger, F. Beutner, B. Isermann, et al., Whole blood
 metabolite profiles reflect changes in energy metabolism in heart failure, Metabolites. 12
 (2022) 216. doi: 10.3390/metabo12030216.
- [9] V.H. Telle-Hansen, J.J. Christensen, G.A. Formo, K.B. Holven, S.M. Ulven, A
 comprehensive metabolic profiling of the metabolically healthy obesity phenotype, Lipids
 Health Dis. 19 (2020) 90. doi: 10.1186/s12944-020-01273-z.
- [10] O.P. Trifonova, P.G. Lokhov, A.I. Archakov, Metabolic profiling of human blood,
 Biochem. Moscow Suppl. Ser. B. 7 (2013) 179–186. doi: 10.1134/S1990750813030128.
- [11] P.S. Reel, S. Reel, E. Pearson, E. Trucco, E. Jefferson, Using machine learning approaches
 for multi-omics data analysis: A review, Biotech. Adv. 49 (2021) 107739. doi:
 10.1016/j.biotechadv.2021.107739.
- [12] S. Albaradei, M. Thafar, A. Alsaedi, C. Van Neste, T. Gojobori, M. Essack, Z. Gao,
 Machine learning and deep learning methods that use omics data for metastasis prediction,
 Comput. Struct. Biotechnol. J. 19 (2021) 5008–5018. doi: 10.1016/j.csbj.2021.09.001.
- 462 [13] I. Guyon, J. Weston, S. Barnhill, V. Vapnik, Gene selection for cancer classification
 463 using support vector machines, Mach. Learn. 46 (2002) 389–422. doi:
 464 10.1023/A:1012487302797.
- 465 [14] D. Chicco, N. Tötsch, G. Jurman, The Matthews correlation coefficient (MCC) is more
 466 reliable than balanced accuracy, bookmaker informedness, and markedness in two-class
 467 confusion matrix evaluation, BioData Mining. 14 (2021) 13. doi: 10.1186/s13040-021468 00244-z.
- 469 [15] L.A. Torre et al., Ovarian cancer statistics, 2018, CA Cancer J. Clin. 68 (2018) 284–296.
 470 doi: 10.3322/caac.21456.
- 471 [16] S.K. Chatterjee B.R. Zetter, Cancer biomarkers: knowing the present and predicting the
 472 future, Future Oncol. 1 (2005) 37–50. doi: 10.1517/14796694.1.1.37.
- 473 [17] A.R. Rao, H.G. Motiwala, O.M.A. Karim, The discovery of prostate-specific antigen,
 474 BJU Inter. 101 (2008) 5–10. doi: 10.1111/j.1464-410X.2007.07138.x.
- [18] E.P. Diamandis, R.C. Bast, Jr., P. Gold, T.M. Chu, J.L. Magnani, Reflection on the
 discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens
 CA125 and CA 19-9, Clin. Chem. 59 (2013) 22-31.
- 478 https://doi.org/10.1373/clinchem.2012.187047
- [19] K. Nustad, R.C. Bast Jr, T.J. Brien, O. Nilsson, P.Seguin, M.R. Suresh, et al., Specificity
 and affinity of 26 monoclonal antibodies against the CA 125 Antigen: First report from the
 ISOBM TD-1 Workshop, Tumor Biol. 17 (2009) 196–219. doi: 10.1159/000217982.
- [20] K. Holcomb, Z. Vucetic, M.C. Miller, R.C. Knapp, Human epididymis protein 4 offers
 superior specificity in the differentiation of benign and malignant adnexal masses in
- 484 premenopausal women, Am. J. Obstet. Gynecol. 205 (2011) 358.e1-6. doi:
- 485 10.1016/j.ajog.2011.05.017.

- 486 [21] I. Hellström, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, M.
- 487 McIntosh, et al., The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer
 488 Res. 63 (2003) 3695–3700.
- [22] S. F. Shariat, P.I. Kaarakiewicz, R. Ashfaq, S.P. Lerner, G.S. Palapattu, R. J. Cote, et al.,
 Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in
 patients undergoing cystectomy, Cancer. 112 (2008) 315–325. doi: 10.1002/cncr.23162.
- 492 [23] K.A. Landers, M.J. Burger, M.A. Tebay, D.M. Purdie, B. Scells, H. Samaratunga, et al.,
- 493 Use of multiple biomarkers for a molecular diagnosis of prostate cancer, Int. J. Cancer 114
 494 (2005) 950–956. doi: 10.1002/ijc.20760.
- 495 [24] D. P. Malinowski, Multiple biomarkers in molecular oncology. I. Molecular diagnostics
 496 applications in cervical cancer detection, Expert Rev. Mol. Diagn. 7 (2007) 117–131. doi:
 497 10.1586/14737159.7.2.117.
- 498 [25] K.N. Kang, E.Y. Koh, J.Y. Jang, C.W. Kim, Multiple biomarkers are more accurate than
 499 a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian
 500 cancer screening, Obstet. Gynecol. Sci. 65 (2022) 346–354. doi: 10.5468/ogs.22017.
- 501 [26] E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, et al.,
 502 Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 (2002) 572–577.
 503 doi: 10.1016/S0140-6736(02)07746-2.
- 504 [27] G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, et al., Serum protein
 505 markers for early detection of ovarian cancer, Proc. Natl. Acad. Sci. USA. 102 (2005) 7677–
 506 7682. doi: 10.1073/pnas.0502178102.
- 507 [28] I. Visintin, Z. Feng, G. Longton, D.C. Ward, A.B. alvero, Y. Lai, et al., Diagnostic
 508 markers for early detection of ovarian cancer, Clin. Cancer Res. 14 (2008) 1065–1072. doi:
 509 10.1158/1078-0432.CCR-07-1569.
- 510 [29] F.R. Ueland, C.P. Desimone, L.G. Seamon, R.A. Miller, S. Goodrich, I. Podzielinski, et
 511 al., Effectiveness of a multivariate index assay in the preoperative assessment of ovarian
 512 tumors, Obstet. Gynecol. 117 (2011) 1289. doi: 10.1097/AOG.0b013e31821b5118.
- [30] R.E. Bristow, A. Smith, Z. Zhang, D.W. Chan, G. Crutcher, E.T. Fung, D. G. Munroe,
 Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay,
 Gynecol. Oncol. 128 (2013) 252–259. doi: 10.1016/j.ygyno.2012.11.022.
- [31] R.R. Urban, T.C. Pappas, R.G. Bullock, D.G. Munroe, V. Bonato, K. Agnew, B.A. Goff,
 Combined symptom index and second-generation multivariate biomarker test for prediction
 of ovarian cancer in patients with an adnexal mass, Gynecol. Oncol. 150 (2018) 318–323.
 doi: 10.1016/j.ygyno.2018.06.004.
- [32] V.A. Hristova D.W. Chan, Cancer biomarker discovery and translation: proteomics and beyond, Expert Rev. Proteo. 16 (2019) 93–103. doi: 10.1080/14789450.2019.1559062.
- [33] M. Lu X. Zhan, The crucial role of multiomic approach in cancer research and clinically
 relevant outcomes, EPMA J. 9 (2018) 77–102. doi: 10.1007/s13167-018-0128-8.
- 524 [34] G. Nicora, F. Vitali, A. Dagliati, N. Geifman, R. Bellazzi, Integrated multi-omics
 525 analyses in oncology: A review of machine learning methods and tools, Front. Oncol. 10
 526 (2020) Accessed: Jun. 05, 2023. [Online]. Available:
- 527 https://www.frontiersin.org/articles/10.3389/fonc.2020.01030
- [35] A. Dhillon, A. Singh, V.K. Bhalla, A systematic review on biomarker identification for
 cancer diagnosis and prognosis in multi-omics: From computational needs to machine
- learning and deep learning, Arch Computat. Methods Eng. 30 (2023) 917–949. doi:
 10.1007/s11831-022-09821-9.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 532 [36] D.A. Gaul, R. Mezencev, T.Q. Long, C.M. Jones, B.B. Benigno, A. Gray, et al., Highly-
- accurate metabolomic detection of early-stage ovarian cancer, Sci. Rep. 5 (2015) 16351.
- 534 doi: 10.1038/srep16351.